Neurocrine Biosciences (NASDAQ: NBIX)
Neurocrine Biosciences Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Neurocrine Biosciences Company Info
Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases.
News & Analysis
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
Investors have grown weary of unpredictable profitability and unexpected expenses.
3 Biotech Stocks With Huge Catalysts This Fall
Clinical trial results expected this fall could send shares of these stocks screaming higher, or lower.
Why Neurocrine Biosciences Stock Jumped Today
The stock is being added to a mid-cap index.
Neurocrine Biosciences Officially Begins Marketing Its New Parkinson's Disease Drug
The much-anticipated launch of Ongentys has arrived.
Parkinson's Disease Patients Get Long-Term Benefits From Experimental Gene Therapy
Three years after treatment with NBIb-1817, Parkinson's disease patients still are still showing improvements.
How Neurocrine Biosciences Crushed It in Q2
The biotech blew past Wall Street estimates with soaring sales of Ingrezza.
Is Now a Good Time To Buy Neurocrine Biosciences?
The biopharmaceutical company has seen shares rise 44.5% in less than two months.
Neurocrine Biosciences Q1 Beats on Earnings, Revenue
The company's Ingrezza continues to power its revenue and profitability growth.
Valuation
Earnings Transcripts
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript
NBIX earnings call for the period ending June 30, 2022.
Neurocrine Biosciences (NBIX) Q1 2022 Earnings Call Transcript
NBIX earnings call for the period ending March 31, 2022.
Neurocrine Biosciences (NBIX) Q4 2021 Earnings Call Transcript
NBIX earnings call for the period ending December 31, 2021.
Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcript
NBIX earnings call for the period ending September 30, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.